TITLE

OREXO SIGNS PACT FOR ABSTRAL IN MIDDLE EAST/AFRICA

PUB. DATE
October 2010
SOURCE
Worldwide Biotech;Oct2010, Vol. 22 Issue 10, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the signing of a licensing and distribution agreement between Orexo OB and NewBridge Pharmaceuticals which gives NewBridge rights to seek approval for the marketing of Orexo's Abstral in Africa and the Middle East. NewBridge president Joe Henein vouches for the product's significant contribution in the treatment of breakthrough cancer pain. NewBridge will also be responsible for the management of the regulatory approval process and the commercialization in 64 countries across those regions.
ACCESSION #
55584202

 

Related Articles

  • OREXO/PROSTRAKAN EXTEND LICENSING PACT FOR RAPINYL (ABSTRAL).  // Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p2 

    The article reports on the extension of the European licensing agreement between Swedish pharmaceutical company Orexo AB and Scottish specialty pharmaceutical company ProStrakan Group PLC. The agreement involves the drug Rapinyl for breakthrough cancer pain and Orexo covering North America....

  • RECIPHARMCOBRA BIOLOGICS GRANTED PLASMID PATENT.  // Audiotex Update;Oct2010, Vol. 22 Issue 10, p1 

    The article offers news briefs related to biotechnology companies worldwide. RecipharmCobra Biologics has been granted patents for the novel plasmid maintenance systems. Results of the new anti-infective compounds for treatment and prevention of antibiotic resistant infections has been unveiled...

  • OREXO PATENT FOR RAPID DELIVERY ISSUED IN EU.  // Worldwide Biotech;May2004, Vol. 16 Issue 5, p3 

    Reports on the European patent that has been granted to Orexo Pharmaceuticals for its sublingual tablet technology. Information on the tablet technology; Product development strategy of Orexo; Details on the Rapinyl product of Orexo.

  • OREXO PRESENTS POSITIVE STUDY RESULTS FOR SUBLINOX.  // Worldwide Biotech;Aug2006, Vol. 18 Issue 8, p2 

    Reports on a positive study result presented by Orexo for Sublinox at Associated Professional Sleep Societies in Salt Lake City, Utah. Efficacy of Sublinox in fast sleep induction; Reason for the competitive advantage of Sublinox in comparison with existing drugs.

  • OREXO'S RAPINYL NEARING REGULATORY DECISION IN EUROPE.  // Worldwide Biotech;Nov2007, Vol. 19 Issue 11, p7 

    The article reports that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) is nearing regulatory decision on Rapinyl, a drug for acute pain treatment from Orexo. The first indication of Rapinyl is breakthrough pain in cancer. The drug is based on...

  • J&J, Orexo in $585M Deal on Preclinical Modulators.  // Bioworld Week;6/7/2010, Vol. 18 Issue 23, p3 

    The article reports on the 585 million dollar deal between the Johnson & Johnson subsidiaries Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV with Orexo AB for the development of preclinical programs targeting pathways that are involved in arachidonic acid metabolism.

  • OREXO'S ASTRAL GETS TWO MORE EU MARKET APPROVALS.  // Worldwide Biotech;Apr2009, Vol. 21 Issue 4, p3 

    The article reports on Marketing Authorizations received by Orexo from the regulatory authorities of France and Spain for AbstralTM, a drug used for the treatment of cancer pain. ProStrakan, Orexo's exclusive licensing partner for AbstralTM in Europe and North America is expected to launch the...

  • OREXO/KYOWA HAKKO KIRIN DISTRIBUTE KW-2246 FOR CANCER PAIN.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p7 

    The article reports on the joint distribution agreement signed between Kyowa Hakko Kirin Co. Ltd. and pharmaceutical firm Hisamitsu Pharmaceutical Co. Inc. Kyowa will primarily handle the approval process for the product in Japan. Under the terms of the agreement, the two companies will jointly...

  • NEWS.  // Pharmaceutical Technology Europe;Aug2003, Vol. 15 Issue 8, p6 

    Presents news updates on the pharmaceutical industry in the U.S. as of August 2003. Decision of Diabact Ab to change its name into Orexo AB; Custom synthesis facility opened by Fisher Scientific Chemicals in Loughborough, England; Novel treatment for solid cancers to be developed by OctoPlus...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics